The overall goal of the Transgenic/Knockout Rodent Core offers state-of-the-art services for the manipulation of mouse and rat genomes, ensuring that the primary beneficiaries of CCSG-supported Shared Resources have the best information and technical resources available to support cancer research. The Core, which is Cancer Center managed, was established in 1993 to produce transgenic and knockout mice for USC Norris members and to increase the use of mouse technology through education and consultation to the cancer research community. Since its inception, the Core has operated under the same faculty leader, Dr. Robert Maxson, and manager, Dr. Nancy Wu; it has also been continuously funded by the CCSG. The Core is widely recognized within the USC community and beyond for the high quality of its services. The Core produces transgenic and knockout mice and offers two important new services, knockout rats and CRISPR/Cas9- mediated gene editing in mice. Using ES cell technology pioneered by Dr. Qi-Long Ying at USC, the Core generated the first knockout rats. The new CRISPR/Cas9 technology will make it possible to produce gene knockouts much faster and at lower cost than current ES cell-based technology. The Core continues to be active in education and consulting services, and provides a number of important ancillary services, including in vitro fertilization, and re-derivation of mouse strains, as well as cryopreservation of embryos. At the last CCSG renewal, the Core received a merit rating of ?excellent? with reviewers noting the competence of the Core leadership and the high quality of the work. The only criticism was low usage by Cancer Center members, although it was recognized that the Core serves the entire USC community. We have stepped up efforts to promote the availability of the Core and encourage cancer investigators to use Core services in their research. In the most recent year, 12 peer-review funded members, or 71% of total users, from four Research Programs (Epigenetics and Regulation, Gastrointestinal Cancers, Molecular Genetics, and Tumor Microenvironment) used the Core to accomplish their research objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-44
Application #
9607928
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2018-12-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications